Asset
LEVOSIMENDAN
Tenax Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03541603 | phase2 | completed | 2018-11-14 | 2020-04-07 | Tenax Therapeutics, Inc. | Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF |
| NCT02025621 | phase3 | completed | 2014-07-01 | 2016-11-01 | Tenax Therapeutics, Inc. | Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass |
| NCT03624010 | phase2 | completed | 2019-04-09 | 2023-04-25 | Tenax Therapeutics, Inc. | Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients |
FDA applications (0)
This company has no applications containing this asset.